KR930017904A - 축합 이미다조피리딘 유도체 - Google Patents

축합 이미다조피리딘 유도체 Download PDF

Info

Publication number
KR930017904A
KR930017904A KR1019930001859A KR930001859A KR930017904A KR 930017904 A KR930017904 A KR 930017904A KR 1019930001859 A KR1019930001859 A KR 1019930001859A KR 930001859 A KR930001859 A KR 930001859A KR 930017904 A KR930017904 A KR 930017904A
Authority
KR
South Korea
Prior art keywords
ring
group
compound
pharmaceutical composition
optionally substituted
Prior art date
Application number
KR1019930001859A
Other languages
English (en)
Other versions
KR100242398B1 (ko
Inventor
스스무 다까다
다까시 사사따니
노부오 죠메이
마꼬또 아다찌
아끼라 마쯔시따
Original Assignee
시오노 요시히꼬
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히꼬, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 시오노 요시히꼬
Publication of KR930017904A publication Critical patent/KR930017904A/ko
Application granted granted Critical
Publication of KR100242398B1 publication Critical patent/KR100242398B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

하기 일반식(I)의 화합물 또는 그의 염 :
상기식에서, R은 임의로 치환된 아릴그룹 또는 임의로 치환된 방향족 헤테로사이클릭 그룹이고, A환은 이를 구성하고 있는 탄소원자 하나이상이 O, S. SO, SO2및/또는 NR1(여기서, R1은 수소, 알킬, 알콕시카보닐, 카바 모일 또는 아실그룹이다)으로 치환될 수 있는 5내지 9원지환족그룹이고/이거나 상기 A환은 치환체로서 알킬그룹을 함유할 수 있다.
본 발명의 화합물은 불안해소제, 마비 길항제 또는 뇌기능 활성제와 같은 향정신성 약제로서 유용하다.

Description

축합 이미다조피리딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(I)의 화합물 또는 그의 염 :
    상기식에서, R은 임의로 치환된 아릴그룹 또는 임의로 치환된 방향족 헤테로사이클릭 그룹이고, A환은 이를 구성하고 있는 탄소원자 하나이상이 O, S. SO, SO2및/또는 NR1(여기서, R1은 수소, 알킬, 알콕시카보닐, 카바 모일 또는 아실그룹이다)으로 치환될 수 있는 5내지 9원지환족그룹이고/이거나 상기 A환은 치환체로서 알킬그룹을 함유할 수 있다.
  2. 제1항에 있어서, R이 임의로 치환된 이소옥사졸릴인 화합물.
  3. 제1항 또는 제2항에 있어서, A환이 디하이드로티오피라노, 사이클로헥세노 또는 디하이드로 피라노 환인 화합물.
  4. 제1항에 있어서, 2-(3-이소옥사졸릴)-1,6,7,9-테트라하이드로이미다조[4,5,-d]피라노[4,5,-d]피리딘 또는 그의 염인 화합물.
  5. 필수 활성 성분으로서 제1항에 청구된 화합물 유효량을 그에 대한 적합한 담체 또는 부형제와 함께 포함하는 약학 조성물.
  6. 향정신성 질환을 치료하기 위한 제5항에 청구된 약학 조성물.
  7. 불안해소제로서 유용한 제5항에 청구된 약학 조성물.
  8. 마비 길항제로서 유용한 제5항에 청구된 약학 조성물.
  9. 뇌 기능 활성제로서 유용한 제5항에 청구된 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930001859A 1992-02-12 1993-02-11 축합 이미다조피리딘 유도체 KR100242398B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP92-59347 1992-02-12
JP5934792 1992-02-12

Publications (2)

Publication Number Publication Date
KR930017904A true KR930017904A (ko) 1993-09-20
KR100242398B1 KR100242398B1 (ko) 2000-03-02

Family

ID=13110672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930001859A KR100242398B1 (ko) 1992-02-12 1993-02-11 축합 이미다조피리딘 유도체

Country Status (12)

Country Link
US (2) US5378848A (ko)
EP (1) EP0556008B1 (ko)
JP (1) JP2863396B2 (ko)
KR (1) KR100242398B1 (ko)
AT (1) ATE153023T1 (ko)
CA (1) CA2088798C (ko)
DE (1) DE69310563T2 (ko)
DK (1) DK0556008T3 (ko)
ES (1) ES2105099T3 (ko)
GR (1) GR3023498T3 (ko)
HU (1) HU218950B (ko)
TW (1) TW221435B (ko)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711257D0 (en) * 1997-05-30 1997-07-30 Smithkline Beecham Plc Novel compounds
GB9720052D0 (en) * 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
TW550080B (en) 1998-11-17 2003-09-01 Shionogi & Co Transdermic preparation comprising cerebral function activating agent
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
BR0109643A (pt) * 2000-03-30 2003-04-22 Shionogi & Co Processo sintético e forma de cristal de derivados condensados da imidazopiridina
WO2003008421A1 (fr) * 2001-07-16 2003-01-30 Shionogi & Co., Ltd. Procede de preparation de derives amidine
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
JPWO2003028723A1 (ja) * 2001-09-27 2005-01-13 埼玉第一製薬株式会社 縮合イミダゾピリジン誘導体を含む経皮吸収用医薬組成物
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
EP1617845A4 (en) * 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2005018556A2 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
ES2406730T3 (es) * 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
CA2540541C (en) * 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005048945A2 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
JP4891088B2 (ja) * 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
JP2007517035A (ja) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
CA2551399A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
CA2559863A1 (en) * 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) * 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006038923A2 (en) * 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) * 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006026760A2 (en) * 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
AU2005322898B2 (en) * 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2597092A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
KR20080048551A (ko) * 2005-09-23 2008-06-02 콜레이 파마시티컬 그룹, 인코포레이티드 1Ｈ-이미다조[4,5-ｃ]피리딘 및 그의 유사체의 제조법
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
TWI321503B (en) 2007-06-15 2010-03-11 Univ Nat Taiwan Science Tech The analytical method of the effective polishing frequency and number of times towards the polishing pads having different grooves and profiles
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
TW201129565A (en) * 2010-01-12 2011-09-01 Hoffmann La Roche Tricyclic heterocyclic compounds, compositions and methods of use thereof
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1263651A (en) * 1984-07-09 1989-12-05 Ciba-Geigy Ag Certain ring-fused pyrazolo ¬3,4-d|-pyridin-3-one derivatives
CA1306260C (en) * 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives

Also Published As

Publication number Publication date
ES2105099T3 (es) 1997-10-16
DK0556008T3 (da) 1997-06-09
CA2088798A1 (en) 1993-08-23
JPH05286973A (ja) 1993-11-02
HU9300376D0 (en) 1993-04-28
HU218950B (hu) 2001-01-29
ATE153023T1 (de) 1997-05-15
GR3023498T3 (en) 1997-08-29
JP2863396B2 (ja) 1999-03-03
KR100242398B1 (ko) 2000-03-02
EP0556008B1 (en) 1997-05-14
HUT70035A (en) 1995-09-28
DE69310563D1 (de) 1997-06-19
US5461062A (en) 1995-10-24
DE69310563T2 (de) 1997-11-13
US5378848A (en) 1995-01-03
EP0556008A1 (en) 1993-08-18
TW221435B (ko) 1994-03-01
CA2088798C (en) 2003-08-05

Similar Documents

Publication Publication Date Title
KR930017904A (ko) 축합 이미다조피리딘 유도체
PT100631A (pt) Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem
FI950016A0 (fi) Heterosykliset yhdisteet lääkeaineena
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
KR900004333A (ko) 맥관 형성 억제제
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
PE20030549A1 (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
PT628311E (pt) Derivado de xantina com actividade antidepressiva
FI882081A0 (fi) 2-substituerade e-fusionerade (1,2,4) triazolo(1,5-c) pyrimidiner, farmaceutiska kompositioner och deras anvaendning.
ES2112386T3 (es) Agentes terapeuticos para uso en el tratamiento de la enfermedad de parkinson.
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
DE69033223D1 (de) Derivate von 6-substituierten azyklischen Pyrimidin-Nukleosiden und diese als Wirkstoff enthaltende antivirale Mittel
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
KR930701446A (ko) 트리사이클릭 벤조디아제핀 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물
KR880013920A (ko) 디하이드로피리딘 화합물 및 이의 제조방법
KR910014119A (ko) 항-고혈압 활성을 갖는 티아졸리딘 유도체 및 그의 치료용도
KR930006024A (ko) 이미다조 인돌리진 유도체 및 그의 제조방법
KR900009640A (ko) 벤족 사제핀 유도체
NO165593C (no) Analogifremgangsmaate ved fremstilling av nye tetracykliske indolderivater.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20061102

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee